# US 2022/0031707 A1 · Pharmaceutical composition for topical use comprising at least one local anaesthetic substance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031707 A1
- Document ID: US20220031707A1
- Status: Published application
- Kind: A1
- Application number: 17/276,315
- Filed: 2019-09-12
- Published: 2022-02-03
- Earliest claimed: 2018-09-17
- Assignees: Societe D'Exploitation De Produits Pour Les Industries Chimiques Seppic
- Applicants: Societe D'Exploitation De Produits Pour Les Industries Chimiques Seppic
- Inventors: Catherine BULCOURT; Alice DENIS; Séverine SIGURANI
- Web page: https://patentgrep.com/patent/US20220031707A1

## CPC

- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 23/02: Local anaesthetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition for topical use which is in the form of a water-in-oil emulsion including, for 100% of the weight thereof: —from 0.3% to 5% by weight of at least one local anaesthetic substance; —from 60% to 90% by weight of gelled aqueous phase; —from 9.7% to 35% by weight of a fatty phase including at least one oil and an emulsifying system including a combination of at least one emulsifying surfactant selected from the elements of the group consisting of alkylpolyglycoside compositions and alkylpolyglycoside and fatty alcohol compositions, and of at least one emulsifying surfactant selected from the elements of the group consisting of polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates.

## Claims

### Claim 1

A pharmaceutical composition suitable for topical use which is in the form of an emulsion of water-in-oil type comprising, per 100% of the composition's weight:
from 0.3% to 5% by weight of at least one local anesthetic substance from the family of the amino amides and/or amino esters,
from 60% to 90% by weight of a gelled aqueous phase (A1)
from 9.7% to 35% by weight of a fatty phase (A2) comprising at least one oil and an emulsifying system comprising a combination of at least one emulsifying surfactant (S1) selected from the elements of the group consisting of compositions of alkyl polyglycosides, and compositions of alkyl polyglycosides and of fatty alcohols, and of at least one emulsifying surfactant (S2) selected from the elements of the group consisting of polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates, and alkoxylated polyglycerol polyhydroxystearates.

### Claim 2 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein the gelled aqueous phase comprises, per 100% of its weight:
from 0.5% to 10% by weight of a crosslinked anionic polyelectrolyte,
from 90% to 99.5% by weight of water.

### Claim 3 (depends on 2)

The pharmaceutical composition as claimed in claim 2, wherein the crosslinked anionic polyelectrolyte comprises a proportion of greater than or equal to 25 mol % of monomer units derived from 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid in free acid or partially or totally salified form.

### Claim 4 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein the local anesthetic substance is chosen from the elements, being in neutral or salt form, of the group consisting of ethyl 4-aminobenzoate (CAS number=94-09-7) or benzocaine of formula (Ia)
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide (CAS number=137-58-6) or lidocaine of formula (Ib)
(RS)—N-(2-methylphenyl)-N2-propylalaninamide (CAS number=721-50-6) or prilocaine in the R enantiomer form of formula (Ic1) and in the S enantiomer form of formula (Ic2)
2-(dimethylamino)ethyl 4-(butylamino)benzoate (CAS number=94-24-6) or tetracaine of formula (Id)
(RS)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide (CAS number=38396-39-3) or bupivacaine of formula (Ie)
N-(2,6-dimethylphenyl)-2-(ethyl(propyl)amino)butanamide (CAS number=36637-18-0) or etidocaine of formula (If)
2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide (CAS number=85-79-0) or cinchocaine of formula (Ig)
2-diethylaminoethyl 4-amino-3-butoxybenzoate (CAS number=99-43-4) or oxybuprocaine of formula (Ih)
4-[3-(4-butoxyphenoxy)propyl]morpholine (CAS number=140-65-8) or pramocaine of formula (Ii)
butyl 4-aminobenzoate (CAS number=94-25-7) or butamben of formula (Ij)
2-(diethylamino)ethyl 3-amino-4-propoxybenzoate (CAS number=499-67-2) or proxymetacaine of formula (Ik)

### Claim 5 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein the local anesthetic substance is chosen from the elements of the group consisting of the hydrochloride, phosphate, nitrate, propionate and citrate salts of the compounds of formula (Ia), (Ib), (Ic1), (Ic2), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij) and (Ik).

### Claim 6 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein the emulsifying surfactant (S1) consists of at least one alkyl polyglycoside composition (C1) represented by formula (VIII):
R1-O-(G)x-H (VIII)
in which x represents a decimal number between 1.05 and 2.5, G represents the glucosyl or β-D-glucopyranosyl radical, obtained from the removal of the hemiacetal hydroxyl group from β-D-glucopyranose, and R1 represents a radical chosen from the elements of the group consisting of the radicals n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl and n-behenyl, said composition (C1) consisting of a mixture of compounds represented by formulae (VIII1), (VIII2), (VIII3), (VIII4) and (VIII5):
R1-O-(G)1-H (VIII1)
R1-O-(G)2-H (VIII2)
R1-O-(G)3-H (VIII3)
R1-O-(G)4-H (VIII4)
R1-O-(G)5-H (VIII5)
in the respective molar proportions a1, a2, a3, a4 and a5, such that:
the sum a1+a2+a3+a4+a5 is equal to 1, and that
the sum a1+2a2+3a3+4a4+5a5 is equal to x.

### Claim 7 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein the emulsifying surfactant (S1) consists of at least one composition (C2) comprising, per 100% of weight:
from 10% to 50% by weight of at least one alkyl polyglycoside composition (C1) represented by formula (VIII):
R1-O-(G)x-H (VIII)
in which x represents a decimal number between 1.05 and 2.5, G represents a glucose residue, and R1 represents a radical chosen from the elements of the group consisting of the radicals n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl and n-behenyl, said composition consisting of a mixture of compounds represented by formulae (VIII1), (VIII2), (VIII3), (VIII4) and (VIII5):
R1-O-(G)1-H (VIII1)
R1-O-(G)2-H (VIII2)
R1-O-(G)3-H (VIII3)
R1-O-(G)4-H (VIII4)
R1-O-(G)5-H (VIII5)
in the respective molar proportions a1, a2, a3, a4 and a5, such that:
the sum a1+a2+a3+a4+a5 is equal to 1, and that
the sum a1+2a2+3a3+4a4+5a5 is equal to x; and
from 90% to 50% by weight of at least one fatty alcohol of formula (IX):
R′1-OH (IX),
in which R′1 represents a radical chosen from the elements of the group consisting of the radicals n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl and n-behenyl, where R′l may be identical to or different from R1.

### Claim 8 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein the emulsifying surfactant (S2) consists of at least one polyglycol polyhydroxystearate represented by formula (XII):
in which y2 represents an integer greater than or equal to 2 and less than or equal to 50, R4 represents a hydrogen atom, a methyl radical or an ethyl radical, and Z2 represents a radical of formula (XIII):
in which y′2 represents an integer greater than or equal to 0 and less than or equal to 10, and Z′2 represents a radical of formula (XIII) as defined above, where Z2′ may be identical to or different from Z2, or a hydrogen atom.

### Claim 9 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein the weight ratio between the emulsifying surfactant (S1) and the emulsifying surfactant (S2) is greater than or equal to ¼ and less than or equal to 1.

### Claim 10 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein that said composition is intended to be used for therapy in a human being or animal.

### Claim 11 (depends on 1)

A method for treating pain, pruritus and/or anorectal disorders in a human being or animal, comprising applying an effective amount of the pharmaceutical composition of claim 1 to the human being or animal in need thereof.

### Claim 12 (depends on 1)

The pharmaceutical composition as claimed in claim 1, wherein said composition being suitable for use in a surgical method in a human being or animal.

### Claim 13 (depends on 1)

A method for anesthetizing an area of the skin, of the scalp or of the mucous membranes of human beings or of animals, comprising applying an effective amount of the pharmaceutical composition of claim 1 to the skin, the scalp, or the mucous membranes of the human being or the animal in need thereof.

### Claim 14 (depends on 1)

The pharmaceutical composition as claimed in claim 1, further comprising at least one or more auxiliary compounds chosen from foaming and/or detergent surfactants, thickening and/or gelling surfactants, thickening and/or gelling agents, stabilizers, film-forming compounds, solvents and cosolvents, hydrotropic agents, plasticizing agents, opacifying agents, pearlescent agents, superfatting agents, sequestering agents, chelating agents, antioxidants, fragrances, essential oils, preservatives, conditioning agents, deodorants, mineral fillers or pigments.

### Claim 15 (depends on 1)

A device which is in a form chosen from a pot, a pump-bottle, a wipe, a mask, a transdermal device, a patch, a poultice, a compress, a tube, or a spray, said device comprising a composition (E1) as defined in claim 1.

### Claim 16 (depends on 2)

The pharmaceutical composition as claimed in claim 2, wherein the local anesthetic substance is chosen from the elements, being in neutral or salt form, of the group consisting of ethyl 4-aminobenzoate (CAS number=94-09-7) or benzocaine of formula (Ia)
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide (CAS number=137-58-6) or lidocaine of formula (Ib)
(RS)—N-(2-methylphenyl)-N2-propylalaninamide (CAS number=721-50-6) or prilocaine in the R enantiomer form of formula (Ic1) and in the S enantiomer form of formula (Ic2)
2-(dimethylamino)ethyl 4-(butylamino)benzoate (CAS number=94-24-6) or tetracaine of formula (Id)
(RS)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide (CAS number=38396-39-3) or bupivacaine of formula (Ie)
N-(2,6-dimethylphenyl)-2-(ethyl(propyl)amino)butanamide (CAS number=36637-18-0) or etidocaine of formula (If)
2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide (CAS number=85-79-0) or cinchocaine of formula (Ig)
2-diethylaminoethyl 4-amino-3-butoxybenzoate (CAS number=99-43-4) or oxybuprocaine of formula (Ih)
4-[3-(4-butoxyphenoxy)propyl]morpholine (CAS number=140-65-8) or pramocaine of formula (Ii)
butyl 4-aminobenzoate (CAS number=94-25-7) or butamben of formula (Ij)
2-(diethylamino)ethyl 3-amino-4-propoxybenzoate (CAS number=499-67-2) or proxymetacaine of formula (Ik)

### Claim 17 (depends on 3)

The pharmaceutical composition as claimed in claim 3, wherein the local anesthetic substance is chosen from the elements, being in neutral or salt form, of the group consisting of ethyl 4-aminobenzoate (CAS number=94-09-7) or benzocaine of formula (Ia)
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide (CAS number=137-58-6) or lidocaine of formula (Ib)
(RS)—N-(2-methylphenyl)-N2-propylalaninamide (CAS number=721-50-6) or prilocaine in the R enantiomer form of formula (Ic1) and in the S enantiomer form of formula (Ic2)
2-(dimethylamino)ethyl 4-(butylamino)benzoate (CAS number=94-24-6) or tetracaine of formula (Id)
(RS)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide (CAS number=38396-39-3) or bupivacaine of formula (Ie)
N-(2,6-dimethylphenyl)-2-(ethyl(propyl)amino)butanamide (CAS number=36637-18-0) or etidocaine of formula (If)
2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide (CAS number=85-79-0) or cinchocaine of formula (Ig)
2-diethylaminoethyl 4-amino-3-butoxybenzoate (CAS number=99-43-4) or oxybuprocaine of formula (Ih)
4-[3-(4-butoxyphenoxy)propyl]morpholine (CAS number=140-65-8) or pramocaine of formula (Ii)
butyl 4-aminobenzoate (CAS number=94-25-7) or butamben of formula (Ij)
2-(diethylamino)ethyl 3-amino-4-propoxybenzoate (CAS number=499-67-2) or proxymetacaine of formula (Ik)

### Claim 18 (depends on 2)

The pharmaceutical composition as claimed in claim 2, wherein the local anesthetic substance is chosen from the elements of the group consisting of the hydrochloride, phosphate, nitrate, propionate and citrate salts of the compounds of formula (Ia), (Ib), (Ic1), (Ic2), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij) and (Ik).

### Claim 19 (depends on 3)

The pharmaceutical composition as claimed in claim 3, wherein the local anesthetic substance is chosen from the elements of the group consisting of the hydrochloride, phosphate, nitrate, propionate and citrate salts of the compounds of formula (Ia), (Ib), (Ic1), (Ic2), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij) and (Ik).

### Claim 20 (depends on 4)

The pharmaceutical composition as claimed in claim 4, wherein the local anesthetic substance is chosen from the elements of the group consisting of the hydrochloride, phosphate, nitrate, propionate and citrate salts of the compounds of formula (Ia), (Ib), (Ic1), (Ic2), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij) and (Ik).
